The Screening, Prevention, Outreach and Treatment for Health Equity (SPOT) Chronic Kidney Disease (CKD) programme is being delivered by NHS Hampshire and Isle of Wight.
It is being delivered in collaboration with pharmaceutical company Boehringer Ingelheim.
Thousands of people across Hampshire and the Isle of Wight are benefitting from earlier diagnosis and support for chronic kidney disease. (Image: Natasha Jay Photography)
It aims to improve kidney disease detection and care by supporting primary care teams in identifying at-risk individuals, delivering timely testing and providing personalised care.
Six GP practices across Southampton, Portsmouth and Gosport have already taken part.
Cam Todd, director of population health and inequalities for NHS Hampshire and Isle of Wight, said: “CKD is often described as a ‘silent condition’ because many people do not experience symptoms until it reaches an advanced stage.
“Through SPOT CKD, we are seeing the impact of proactively identifying patients earlier and supporting them to access treatment sooner.
“The programme is helping people understand their condition and take positive steps to protect their health.”
The work supports the government’s 10-Year Plan by focusing on prevention, earlier diagnosis and reducing health inequalities.
Early results show improved identification and management of CKD, especially in deprived areas.